Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Prevention of Meningococcal Disease”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT01682876
What this trial is testing

Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age.

Who this might be right for
Meningococcal DiseaseInfections, Meningococcal
GlaxoSmithKline 715
Post-approval studies (Phase 4)WithdrawnNCT03431675
What this trial is testing

Ciprofloxacin for the Prevention of Meningococcal Meningitis 2018

Who this might be right for
Meningitis, Meningococcal
Epicentre
Post-approval studies (Phase 4)Study completedNCT00271479
What this trial is testing

Fractional Dose Tetravalent A, C, Y, W135 Meningococcal Polysaccharide Vaccine

Who this might be right for
Infections, MeningococcalMeningitis, Meningococcic
Epicentre 720
Testing effectiveness (Phase 2)Study completedNCT00488683
What this trial is testing

B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants

Who this might be right for
Meningococcal Disease
Novartis Vaccines 216
Large-scale testing (Phase 3)Study completedNCT01423084
What this trial is testing

Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years

Who this might be right for
Meningococcal DiseaseMeningococcal Meningitis
Novartis 344
Large-scale testing (Phase 3)Study completedNCT01911221
What this trial is testing

A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive.

Who this might be right for
Prevention of the Meningococcal Disease
Novartis Vaccines 13
Large-scale testing (Phase 3)Study completedNCT01139021
What this trial is testing

One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age

Who this might be right for
Meningococcal Disease
Novartis Vaccines 508
Testing effectiveness (Phase 2)Study completedNCT00262028
What this trial is testing

Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Children

Who this might be right for
Prevention of Meningococcal Disease
Novartis Vaccines 910
Post-approval studies (Phase 4)Study completedNCT00936962
What this trial is testing

Evaluation of Meningococcal C Vaccine Programmes in Canadian Children

Who this might be right for
Meningococcal Sero-type C Infection
University of British Columbia 452
Post-approval studies (Phase 4)Looking for participantsNCT07252804
What this trial is testing

Immunogenicity and Safety of MenB Vaccine in Pediatric Patients With Autoimmune Rheumatic Diseases

Who this might be right for
Autoimmune Rheumatologic Disease
University of Sao Paulo General Hospital 263
Large-scale testing (Phase 3)Study completedNCT00661713
What this trial is testing

Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination Schedules

Who this might be right for
Meningococcal Disease
Novartis Vaccines 1,631
Large-scale testing (Phase 3)Study completedNCT00847145
What this trial is testing

Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers

Who this might be right for
Meningococcal Disease
Novartis Vaccines 2,249
Large-scale testing (Phase 3)Study completedNCT00311415
What this trial is testing

Immunogenicity, Safety, Tolerability and Ability to Prime for Memory of Meningococcal C Conjugate Vaccine in Healthy Children

Who this might be right for
Prevention of Meningococcal Infection
Novartis Vaccines 257
Testing effectiveness (Phase 2)Study completedNCT00262041
What this trial is testing

Study of the Safety and Immune Response of a Meningococcal Conjugate Vaccine Administered to Healthy Adolescents

Who this might be right for
Prevention of Meningococcal Disease
Novartis Vaccines 524
Large-scale testing (Phase 3)Study completedNCT00291343
What this trial is testing

Immune Response & Safety of GSK Biologicals' Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study

Who this might be right for
Infections, Meningococcal
GlaxoSmithKline 296
Testing effectiveness (Phase 2)Study completedNCT01027351
What this trial is testing

Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of Booster Doses of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received One or Four Doses of the Same Vaccine

Who this might be right for
Meningococcal Disease
Novartis Vaccines 163
Large-scale testing (Phase 3)Study completedNCT00443846
What this trial is testing

RotaTeq® and Meningococcus C Vaccine in Healthy Infants (V260-016)

Who this might be right for
Meningitis, MeningococcalRotavirus Infections
Merck Sharp & Dohme LLC 247
Post-approval studies (Phase 4)Study completedNCT00316654
What this trial is testing

Persistence of Antibody Response to N. Meningitidis Group C in Children

Who this might be right for
Prevention of Meningococcal Infection
Novartis Vaccines 489
Large-scale testing (Phase 3)Study completedNCT00626327
What this trial is testing

Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers

Who this might be right for
Meningococcal Infections
Novartis Vaccines 1,630
Not applicableNot Yet RecruitingNCT07671014
What this trial is testing

Metagenomic Analysis of the Pharynx in High Risk Partners

Who this might be right for
GonorrheaNeisseria GonorrheaNeisseria Meningitidis+1 more
Guy's and St Thomas' NHS Foundation Trust 100
Next Page